|
1
|
Bishop MW and Janeway KA: Emerging
concepts for PI3K/mTOR inhibition as a potential treatment for
osteosarcoma. F1000Res. 5(pii): F10002016.doi:
10.12688/f1000research.8228.1. PubMed/NCBI
|
|
2
|
Picci P: Osteosarcoma (osteogenic
sarcoma). Orphanet J Rare Dis. 2:62007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Whelan J, Seddon B and Perisoglou M:
Management of osteosarcoma. Curr Treat Options Oncol. 7:444–455.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Longhi A, Errani C, De Paolis M, Mercuri M
and Bacci G: Primary bone osteosarcoma in the pediatric age: State
of the art. Cancer Treat Rev. 32:423–436. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wan J and Zhang X, Liu T and Zhang X:
Strategies and developments of immunotherapies in osteosarcoma.
Oncol Lett. 11:511–520. 2016.PubMed/NCBI
|
|
6
|
Vos HI, Coenen MJ, Guchelaar HJ and Te Loo
DM: The role of pharmacogenetics in the treatment of osteosarcoma.
Drug Discov Today. 21:1775–1786. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Serra M and Hattinger CM: The
pharmacogenomics of osteosarcoma. Pharmacogenomics J. May
31–2016.(Epub ahead of print). doi: 10.1038/tpj.2016.45. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hu K, Dai HB and Qiu ZL: mTOR signaling in
osteosarcoma: Oncogenesis and therapeutic aspects (Review). Oncol
Rep. 36:1219–1225. 2016.PubMed/NCBI
|
|
9
|
Qiu Q, Jiang J, Lin L, Cheng S, Xin D,
Jiang W, Shen J and Hu Z: Downregulation of RSK2 influences the
biological activities of human osteosarcoma cells through
inactivating AKT/mTOR signaling pathways. Int J Oncol.
48:2508–2520. 2016.PubMed/NCBI
|
|
10
|
Zhao J, Chen F, Zhou Q, Pan W, Wang X, Xu
J, Ni L and Yang H: Aberrant expression of microRNA-99a and its
target gene mTOR associated with malignant progression and poor
prognosis in patients with osteosarcoma. Onco Targets Ther.
9:1589–1597. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bilbao-Aldaiturriaga N, Askaiturrieta Z,
Granado-Tajada I, Goričar K, Dolžan V, Garcia-Miguel P, de andoin N
Garcia, Martin-Guerrero I and Garcia-Orad A: For The Slovenian
Osteosarcoma Study Group: A systematic review and meta-analysis of
MDM2 polymorphisms in osteosarcoma susceptibility. Pediatr Res.
80:472–479. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yu C and Wang W: Relationship between P15
gene mutation and formation and metastasis of malignant
osteosarcoma. Med Sci Monit. 22:656–661. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang C, Yang L, Geng YD, An FL, Xia YZ,
Guo C, Luo JG, Zhang LY, Guo QL and Kong LY: Icariside II, a
natural mTOR inhibitor, disrupts aberrant energy homeostasis via
suppressing mTORC1-4E-BP1 axis in sarcoma cells. Oncotarget.
7:27819–27837. 2016.PubMed/NCBI
|
|
14
|
Kalmár A, Péterfia B, Hollósi P, Galamb O,
Spisák S, Wichmann B, Bodor A, Tóth K, Patai ÁV, Valcz G, et al:
DNA hypermethylation and decreased mRNA expression of MAL, PRIMA1,
PTGDR and SFRP1 in colorectal adenoma and cancer. BMC Cancer.
15:7362015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Qiu X, Hu B, Huang Y, Deng Y, Wang X and
Zheng F: Hypermethylation of ACP1, BMP4, and TSPYL5 in
hepatocellular carcinoma and their potential clinical significance.
Dig Dis Sci. 61:149–157. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Choudhury JH and Ghosh SK: Promoter
hypermethylation profiling identifies subtypes of head and neck
cancer with distinct viral, environmental, genetic and survival
characteristics. PLoS One. 10:e01298082015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang L, Ge J, Ma T, Zheng Y, Lv S, Li Y
and Liu S: Promoter hypermethylation of the cysteine protease RECK
may cause metastasis of osteosarcoma. Tumour Biol. 36:9511–9516.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sonaglio V, de Carvalho AC, Toledo SR,
Salinas-Souza C, Carvalho AL, Petrilli AS, de Camargo B and Vettore
AL: Aberrant DNA methylation of ESR1 and p14ARF genes could be
useful as prognostic indicators in osteosarcoma. Onco Targets Ther.
6:713–723. 2013.PubMed/NCBI
|
|
19
|
Kresse SH, Rydbeck H, Skårn M, Namløs HM,
Barragan-Polania AH, Cleton-Jansen AM, Serra M, Liestøl K,
Hogendoorn PC, Hovig E, et al: Integrative analysis reveals
relationships of genetic and epigenetic alterations in
osteosarcoma. PLoS One. 7:e482622012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Namløs HM, Meza-Zepeda LA, Barøy T,
Østensen IH, Kresse SH, Kuijjer ML, Serra M, Bürger H,
Cleton-Jansen AM and Myklebost O: Modulation of the osteosarcoma
expression phenotype by microRNAs. PLoS One. 7:e480862012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ni QF, Tian Y, Kong LL, Lu YT, Ding WZ and
Kong LB: Latexin exhibits tumor suppressor potential in
hepatocellular carcinoma. Oncol Rep. 31:1364–1372. 2014.PubMed/NCBI
|
|
22
|
Muthusamy V, Premi S, Soper C, Platt J and
Bosenberg M: The hematopoietic stem cell regulatory gene latexin
has tumor-suppressive properties in malignant melanoma. J Invest
Dermatol. 133:1827–1833. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li Y, Basang Z, Ding H, Lu Z, Ning T, Wei
H, Cai H and Ke Y: Latexin expression is downregulated in human
gastric carcinomas and exhibits tumor suppressor potential. BMC
Cancer. 11:1212011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xue ZX, Zheng JH, Zheng ZQ, Cai JL, Ye XH,
Wang C, Sun WJ, Zhou X, Lu MD, Li PH, et al: Latexin inhibits the
proliferation of CD133+ miapaca-2 pancreatic cancer
stem-like cells. World J Surg Oncol. 12:4042014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Abd Elmageed ZY, Moroz K and Kandil E:
Clinical significance of CD146 and latexin during different stages
of thyroid cancer. Mol Cell Biochem. 381:95–103. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wu X, Ye Y, Rosell R, Amos CI, Stewart DJ,
Hildebrandt MA, Roth JA, Minna JD, Gu J, Lin J, et al: Genome-wide
association study of survival in non-small cell lung cancer
patients receiving platinum-based chemotherapy. J Natl Cancer Inst.
103:817–825. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kaur J, Adya R, Tan BK, Chen J and Randeva
HS: Identification of chemerin receptor (ChemR23) in human
endothelial cells: Chemerin-induced endothelial angiogenesis.
Biochem Biophys Res Commun. 391:1762–1768. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Han JA, Kim JY and Kim JI: Analysis of
gene expression in cyclooxygenase-2-overexpressed human
osteosarcoma cell lines. Genomics Inform. 12:247–253. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sun DX, Liao GJ, Liu KG and Jian H:
Endosialin-expressing bone sarcoma stem-like cells are highly
tumor-initiating and invasive. Mol Med Rep. 12:5665–5670.
2015.PubMed/NCBI
|
|
30
|
Song L and Li Y: The role of stem cell DNA
methylation in colorectal carcinogenesis. Stem Cell Rev.
12:573–583. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xu P, Hu G, Luo C and Liang Z: DNA
methyltransferase inhibitors: An updated patent review (2012–2015).
Expert Opin Ther Pat. 26:1017–1030. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xie P, Zang LQ, Li XK and Shu Q: An
epigenetic view of developmental diseases: New targets, new
therapies. World J Pediatr. 12:291–297. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lizarraga F, Ceballos-Cancino G, Espinosa
M, Vazquez-Santillan K, Maldonado V and Melendez-Zajgla J: Tissue
inhibitor of metalloproteinase-4 triggers apoptosis in cervical
cancer cells. PLoS One. 10:e01359292015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu X, Liang Z, Gao K, Li H, Zhao G, Wang
S and Fang J: MicroRNA-128 inhibits EMT of human osteosarcoma cells
by directly targeting integrin alpha2. Tumour Biol. 37:7951–7957.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tian Z, Guo B, Yu M, Wang C, Zhang H,
Liang Q, Jiang K and Cao L: Upregulation of micro-ribonucleic
acid-128 cooperating with downregulation of PTEN confers metastatic
potential and unfavorable prognosis in patients with primary
osteosarcoma. Onco Targets Ther. 7:1601–1608. 2014.PubMed/NCBI
|
|
36
|
Shen L, Chen XD and Zhang YH: MicroRNA-128
promotes proliferation in osteosarcoma cells by downregulating
PTEN. Tumour Biol. 35:2069–2074. 2014. View Article : Google Scholar : PubMed/NCBI
|
